{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T13:29:55Z","timestamp":1789651795146,"version":"4.0.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,8,8]],"date-time":"2018-08-08T00:00:00Z","timestamp":1533686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00277-018-3437-z","type":"journal-article","created":{"date-parts":[[2018,8,8]],"date-time":"2018-08-08T14:34:33Z","timestamp":1533738873000},"page":"2129-2135","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?"],"prefix":"10.1007","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2308-6666","authenticated-orcid":false,"given":"Charlott","family":"M\u00f6rth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios","family":"Valachis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal Abu","family":"Sabaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Molin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Flogeg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunilla","family":"Enblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,8]]},"reference":[{"issue":"9","key":"3437_CR1","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1038\/bjc.2015.94","volume":"112","author":"A Smith","year":"2015","unstructured":"Smith A et al (2015) Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK\u2019s Haematological Malignancy Research Network. Br J Cancer 112(9):1575\u20131584","journal-title":"Br J Cancer"},{"issue":"4","key":"3437_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235\u2013242","journal-title":"N Engl J Med"},{"issue":"11","key":"3437_CR3","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","volume":"12","author":"M Pfreundschuh","year":"2011","unstructured":"Pfreundschuh M et al (2011) CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 12(11):1013\u20131022","journal-title":"Lancet Oncol"},{"issue":"4","key":"3437_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123978","volume":"10","author":"A Gutierrez","year":"2015","unstructured":"Gutierrez A et al (2015) Differential impact of relative dose-intensity reductions in diffuse large B-cell lymphoma treated with R-CHOP21 or R-CHOP14. PLoS One 10(4):e0123978","journal-title":"PLoS One"},{"issue":"9","key":"3437_CR5","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00277-010-0956-7","volume":"89","author":"T Hirakawa","year":"2010","unstructured":"Hirakawa T et al (2010) Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma. Ann Hematol 89(9):897\u2013904","journal-title":"Ann Hematol"},{"key":"3437_CR6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/1756-9966-28-116","volume":"28","author":"Y Terada","year":"2009","unstructured":"Terada Y et al (2009) Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma. J Exp Clin Cancer Res 28:116","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"3437_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00277-015-2514-9","volume":"95","author":"Y Utsu","year":"2016","unstructured":"Utsu Y et al (2016) Influence of dose reduction of vincristine in R-CHOP on outcomes of diffuse large B cell lymphoma. Ann Hematol 95(1):41\u201347","journal-title":"Ann Hematol"},{"issue":"1","key":"3437_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3960\/jslrt.51.1","volume":"51","author":"H Yamaguchi","year":"2011","unstructured":"Yamaguchi H, Hirakawa T, Inokuchi K (2011) Importance of relative dose intensity in chemotherapy for diffuse large B-cell lymphoma. J Clin Exp Hematop 51(1):1\u20135","journal-title":"J Clin Exp Hematop"},{"issue":"6","key":"3437_CR9","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/COC.0000000000000141","volume":"37","author":"L Balducci","year":"2014","unstructured":"Balducci L et al (2014) Retrospective analysis of relative dose intensity in patients with non-Hodgkin lymphoma receiving CHOP-based chemotherapy and pegfilgrastim. Am J Clin Oncol 37(6):603\u2013610","journal-title":"Am J Clin Oncol"},{"issue":"28","key":"3437_CR10","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ et al (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33(28):3199\u20133212","journal-title":"J Clin Oncol"},{"key":"3437_CR11","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/blood.V21.5.640.640","volume":"21","author":"PP Carbone","year":"1963","unstructured":"Carbone PP et al (1963) Clinical studies with vincristine. Blood 21:640\u2013647","journal-title":"Blood"},{"key":"3437_CR12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.neulet.2014.10.014","volume":"596","author":"VA Carozzi","year":"2015","unstructured":"Carozzi VA, Canta A, Chiorazzi A (2015) Chemotherapy-induced peripheral neuropathy: what do we know about mechanisms? Neurosci Lett 596:90\u2013107","journal-title":"Neurosci Lett"},{"issue":"10","key":"3437_CR13","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1002\/1097-0142(19940515)73:10<2515::AID-CNCR2820731011>3.0.CO;2-G","volume":"73","author":"N Haim","year":"1994","unstructured":"Haim N et al (1994) Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. Cancer 73(10):2515\u20132519","journal-title":"Cancer"},{"issue":"7","key":"3437_CR14","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/annonc\/mdx097","volume":"28","author":"A Younes","year":"2017","unstructured":"Younes A et al (2017) International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol 28(7):1436\u20131447","journal-title":"Ann Oncol"},{"issue":"19","key":"3437_CR15","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","volume":"117","author":"E Campo","year":"2011","unstructured":"Campo E et al (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117(19):5019\u20135032","journal-title":"Blood"},{"issue":"3","key":"3437_CR16","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1517\/17425255.2014.885016","volume":"10","author":"R Said","year":"2014","unstructured":"Said R, Tsimberidou AM (2014) Pharmacokinetic evaluation of vincristine for the treatment of lymphoid malignancies. Expert Opin Drug Metab Toxicol 10(3):483\u2013494","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"3437_CR17","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1470-2045(08)70078-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M et al (2008) Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol 9(5):435\u2013444","journal-title":"Lancet Oncol"},{"key":"3437_CR18","unstructured":"Aviles, A., et al. (2018) Adjuvant radiotherapy in patients with diffuse large B-cell lymphoma in advanced stage (III\/IV) improves the outcome in the rituximab era. Hematology 1\u20135"},{"issue":"11","key":"3437_CR19","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2013.51.4505","volume":"32","author":"G Held","year":"2014","unstructured":"Held G et al (2014) Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol 32(11):1112\u20131118","journal-title":"J Clin Oncol"},{"issue":"1","key":"3437_CR20","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/annonc\/mdl327","volume":"18","author":"V Boehme","year":"2007","unstructured":"Boehme V et al (2007) Incidence and risk factors of central nervous system recurrence in aggressive lymphoma\u2014a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin\u2019s Lymphoma Study Group (DSHNHL). Ann Oncol 18(1):149\u2013157","journal-title":"Ann Oncol"},{"key":"3437_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ejca.2016.12.029","volume":"75","author":"TC El-Galaly","year":"2017","unstructured":"El-Galaly TC et al (2017) The number of extranodal sites assessed by PET\/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: an international multicenter study of 1532 patients treated with chemoimmunotherapy. Eur J Cancer 75:195\u2013203","journal-title":"Eur J Cancer"},{"issue":"26","key":"3437_CR22","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","volume":"34","author":"N Schmitz","year":"2016","unstructured":"Schmitz N et al (2016) CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 34(26):3150\u20133156","journal-title":"J Clin Oncol"},{"issue":"7","key":"3437_CR23","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00277-010-1150-7","volume":"90","author":"WM Tai","year":"2011","unstructured":"Tai WM et al (2011) Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Ann Hematol 90(7):809\u2013818","journal-title":"Ann Hematol"},{"issue":"5","key":"3437_CR24","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1093\/annonc\/mdp432","volume":"21","author":"D Villa","year":"2010","unstructured":"Villa D et al (2010) Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol 21(5):1046\u20131052","journal-title":"Ann Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-018-3437-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3437-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3437-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T21:19:09Z","timestamp":1571692749000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-018-3437-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,8]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["3437"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3437-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,8]]},"assertion":[{"value":"4 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the local review board in Uppsala, Sweden (Dnr 2014\/233).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}